AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Rao Srinivas sold (to issuer) 3,500 shares of ATAI (indirect holdings)

Rao Srinivas (See remarks) sold (to issuer) 3,500 indirectly-held shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Original reporting
SEC EDGAR · Rao Srinivas
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Neutral
high confidence
Mentioned
$ATAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAINeutralLow
01

Why it matters

The 3,500‑share sale by a director is a routine disclosure with limited market impact.

02

Market read

Minor insider sell; unlikely to influence trading decisions.

03

What to watch

Potential future buyback or secondary offering could make the sale more relevant, but not indicated.

Relevance 4/10Novelty 4/10Timing: reported on 2026-09-11

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ATAINeutralHigh confidence
Context

Officer/director Rao Srinivas sold 3,500 shares of AtaiBeckley Inc. via a Form 4 filing.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The transaction size is small relative to market cap and no price was disclosed, so traders have little actionable insight.

Market effects

Sector

None; the sale does not affect the broader biotech sector.

Regional

None; limited to the company.

Global

None

Counterpoint

What could challenge this read

If the insider had inside knowledge, the sale could hint at upcoming negative news, but no evidence supports this.

Key entities

  • Company
    AtaiBeckley Inc.

    Biotech firm listed on NASDAQ under ticker ATAI.

  • Insider
    Rao Srinivas

    Officer and director of AtaiBeckley Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min